In conclusion, treatment selection in CLL patients must involve a preliminary assessment of clinical (disease stage, age, fitness), biological (IGHV and TP53 status, hematologic and serological parameters), and molecular factors (7). Here, TP53 is linked to B-cell chronic lymphocytic leukemia.